n°124

February 2012

Issue Contents
Editorial

Free  Patients want to know

p.32
Less advice, more explanations

Marketing Authorisations

Dabigatran and atrial fibrillation (New Indication)

p.33-36
The alternative to warfarin for selected patients

Eribulin (New Drug)

p.37-39
Heavily pretreated breast cancer: uncertain advantages, excessive adverse effects

INN common stem: -sartan

p.39

Adverse Effects

Ambulatory care in France: too many adverse events

p.40-41
At least 40% preventable

Free  Mobility aid-related accidents in children

p.42
Wheelchairs, crutches and walkers

Varenicline: aggression and homicidal ideation

p.42-43
Do not use

Thalidomide: deafness

p.43
Monitoring of patients is key

Fixed-dose glucose-lowering drug combinations: preventable lactic acidosis

p.43
Risk of overdose

Drospirenone: venous thrombosis (continued)

p.43
Levonorgestrel or norethindrone are safer

Reviews

Pregnancy and alcohol

p.44-50
Occasional, light drinking may be safe

Pregnancy: another opportunity to raise the issue of alcohol

p.46

Anti-alcohol medication and pregnancy: weighing the risks

p.48

Prescrire's advice

p.49
Alcohol during pregnancy: inform women, without overdramatising or inducing feelings of guilt

Outlook

Learning from errors: a workshop for personal and collective reflection

p.51-54
Overcoming reluctance

Describing errors: excerpts from 4 reports

p.53

Free  Pharmaceutical quality: big pharma also at fault

p.54
Raw materials and manufacturing practices

Free  How a review in Prescrire is produced

p.56

Masthead

Free  Masthead

p.30

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe